Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neutrogena “Barrier” Sunscreen Claim Could Mislead – NARB Decision

This article was originally published in The Tan Sheet

Executive Summary

Industry self-regulation appellate panel upholds a NAD December 2013 decision recommending J&J discontinue the “water + sun barrier” claim on labeling for Neutrogena Beach Defense sunscreen products. But in other contexts comparing sunscreens to barriers is not likely to mislead consumers, NARB says.

You may also be interested in...



J&J Fights NAD Neutrogena Decision Assailing Sunscreen “Barrier”

In a challenge brought by Coppertone sunscreen products marketer Merck & Co., NAD reviews claims for Neutrogena in print, online and in-store advertising, as well as on packaging for Neutrogena Beach Defense lotion and spray. J&J argues its claim uses same term as FDA’s online “Sun Protection” page.

FDA Strengthens Sunscreen Testing And Label Requirements

As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel